MMWR Morb Mortal Wkly Rep. 1997 Jan 31;46(4):79-83.
The Advisory Committee on Immunization Practices (ACIP) recently recommended a sequential vaccination schedule of two doses of inactivated poliovirus vaccine (IPV) followed by two doses of oral poliovirus vaccine (OPV) for routine vaccination of children in the United States (1). ACIP revised its recommendation for routine poliovirus vaccination for three reasons: 1) paralytic poliomyelitis attributable to indigenously acquired wild poliovirus has not occurred in the United States since 1979 (2), 2) progress toward global eradication of poliomyelitis has reduced the risk for importation of wild poliovirus into the United States (3), and 3) vaccine-associated paralytic poliomyelitis (VAPP) continues to occur. ACIP has recommended that implementation of this new vaccination schedule begin in early 1997. This report summarizes both the epidemiology of paralytic poliomyelitis in the United States reported during 1980-1994 and provisional reports for 1995-1996 and updates the estimated risk for VAPP. These findings indicate that the overall estimated risk for VAPP has remained constant.
免疫实践咨询委员会(ACIP)最近建议采用两剂灭活脊髓灰质炎病毒疫苗(IPV),随后接种两剂口服脊髓灰质炎病毒疫苗(OPV)的序贯接种程序,用于美国儿童的常规疫苗接种(1)。ACIP修订其常规脊髓灰质炎病毒疫苗接种建议有三个原因:1)自1979年以来,美国未发生因本土获得的野生脊髓灰质炎病毒导致的麻痹性脊髓灰质炎(2);2)全球根除脊髓灰质炎的进展降低了野生脊髓灰质炎病毒传入美国的风险(3);3)疫苗相关麻痹性脊髓灰质炎(VAPP)仍有发生。ACIP建议于1997年初开始实施这一新的疫苗接种程序。本报告总结了1980 - 1994年期间美国报告的麻痹性脊髓灰质炎的流行病学情况以及1995 - 1996年的临时报告,并更新了VAPP的估计风险。这些结果表明,VAPP的总体估计风险保持不变。